CEO David Goldstein, a geneticist, describes his frustration with patient care when medicines were lacking rare genetic diseases, and how it motivated him to embark on drug development. Actio's lead program targets KCNT-1 and is in the clinic - preclinical animal work showed that inhibiting the target worked well, and that it may be less of a developmental condition. Coverage brought to you by